Johnson & Johnson (JNJ) Other Gross PP&E Adjustments (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Other Gross PP&E Adjustments came in at $49.6 billion in Q1 2026, up 8.09% year-on-year from $45.9 billion in Q1 2025, and down 8.77% quarter-over-quarter from $54.4 billion in Q4 2025.
Johnson & Johnson (JNJ) Other Gross PP&E Adjustments (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Other Gross PP&E Adjustments across 18 years of filings, most recently posting $49.6 billion for Q1 2026.
- Other Gross PP&E Adjustments for Q1 2026 came in at $49.6 billion, up 8.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.6 billion (up 8.09% YoY), and the FY2025 annual result was $54.4 billion, up 11.47% from the prior year.
- Other Gross PP&E Adjustments came in at $49.6 billion for Q1 2026 at Johnson & Johnson, down from $54.4 billion in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $54.4 billion in Q4 2025 to a low of $41.1 billion in Q4 2023.
- The 5-year median for Other Gross PP&E Adjustments is $45.7 billion (2023), against an average of $46.0 billion.
- Across the five-year window, Other Gross PP&E Adjustments soared 5305.78% in 2022 and slipped 8.69% in 2023, its largest moves.
- Johnson & Johnson's Other Gross PP&E Adjustments stood at $42.4 billion in 2022, then advanced by 12.73% to $47.8 billion in 2023, then gained by 2.08% to $48.8 billion in 2024, then rose by 11.47% to $54.4 billion in 2025, then slipped by 8.77% to $49.6 billion in 2026.
- The last three Other Gross PP&E Adjustments figures came in at $49.6 billion (Q1 2026), $54.4 billion (Q4 2025), and $48.9 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | -941.03 Mn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 49.60 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | - |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | - |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | -2.70 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 8.42 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | -1.53 Bn |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 49.60 Bn |
| Mar 29, 2026 | 49.60 Bn |
| Dec 28, 2025 | 54.36 Bn |
| Dec 28, 2025 | 54.36 Bn |
| Sep 28, 2025 | 48.88 Bn |
| Sep 28, 2025 | 48.88 Bn |
| Jun 29, 2025 | 47.97 Bn |
| Jun 29, 2025 | 47.97 Bn |
| Mar 30, 2025 | 45.88 Bn |
| Mar 30, 2025 | 45.88 Bn |
| Dec 29, 2024 | 48.77 Bn |
| Dec 29, 2024 | 48.77 Bn |
| Sep 29, 2024 | 44.77 Bn |
| Sep 29, 2024 | 44.77 Bn |
| Jun 30, 2024 | 43.54 Bn |
| Jun 30, 2024 | 43.54 Bn |
| Mar 31, 2024 | 43.29 Bn |
| Mar 31, 2024 | 43.29 Bn |
| Dec 31, 2023 | 47.78 Bn |
| Dec 31, 2023 | 47.78 Bn |